ROBOSENSE
22.12.2021 17:02:05 CET | Business Wire | Press release
RoboSense LiDAR , the leading smart LiDAR sensor provider, announced it will be exhibiting its latest cutting-edge LiDAR solutions at the Consumer Electronics Show (CES) on January 5 - 8 , 2022, starring RS-LiDAR M1 (M1), the world's first mass-produced automotive grade MEMS solid-state LiDAR. M1 will be joined at the stand by RS-Helios, the newest-generation bespoke LiDAR. RoboSense invites CES 2022 attendees to the West Hall, Tech East , Booth #6861, in Las Vegas, USA .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005289/en/
RoboSense is currently the only company in the world to have achieved mass-produced delivery of front-loading smart solid-state LiDAR. Looking ahead, RoboSense is sustainably empowered for the advent of the mass-produced LiDAR era with M1. Throughout 2021, RoboSense earned a large number of pre-installed fixed-point project orders from auto companies around the world, including the GAC Aion, WM Motor, ZEEKR (a Geely holding company), Lotus Cars, and Inceptio Technology.
M1’s extra small size makes it exceptionally convenient for front loading in mass production models. It is equipped with a unique smart "GAZE" function, which can dynamically and intelligently switch between far-field and near-field perception, substantially leveling up the performance of smart driving systems in different scenes.
This year, M1 has also been recognized for its innovation excellence and contribution to advancing smart mobility, winning a prestigious 2021 Automotive News PACE Award and a 2021 CLEPA Award from the European Association of Automotive Suppliers.
RoboSense is garnering worldwide recognition for its complete innovative portfolio in LiDAR and AI perception solutions. This is proven by its representing 10% of the global automotive pre-installed market, which ranks 1st in China and 2nd worldwide .
Taking the global stage at CES 2022, RoboSense will exhibit the latest LiDAR products and proven LiDAR technologies, including but not limited:
- RS-LiDAR-M1 , SOP version automotive-grade solid-state LiDAR
- RS-HELIOS-5515 , super-wide vertical FoV LiDAR
- RS-Bpearl , industrial unique design blind spot LiDAR
- RS-Ruby , upgraded 128-beam mechanical LiDAR
- RS-Ruby Lite , upgraded 80-beam mechanical LiDAR
- RS-Reference , full-stalk ground truth reference system
With RoboSense’s CES 2022 exhibition around the corner, all attendees - including clients, journalists, analysts, and industry partners - are welcome to visit RoboSense’s booth for detailed solution introductions and live product demonstrations. To schedule a meeting with RoboSense LiDAR and get exclusive access to news, or collaborate on upcoming stories and trends, please reach out to grace.ye@robosense.cn directly. An exciting world of smart mobility awaits.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005289/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom